Any condition that, in the opinion of the investigator, would preclude participation in the study (e.g. chronic alcoholism, drug abuse)
Evidence of vitreoretinal interface abnormality after ocular exam or OCT that may be contributing to the macular edema
An eye that, in the investigator's opinion, has no chance of improving in visual acuity following resolution of macular edema (e.g. presence of subretinal fibrosis or geographic atrophy)
Presence of another ocular condition that may affect the visual acuity or macular edema during the course of the study (e.g. AMD, uveitis, Irvine-Gas)
Evidence of active neovascularization of the iris or retina
Evidence of central atrophy or fibrosis in the study eye
Presence of substantial cataract, one that might decrease the vision by 3 or more lines of vision at sometime during the study.
Previous use of intraocular or periocular corticosteroids in the study eye in the previous 120 days
Previous treatment with anti-angiogenic drugs in the study eye i.e. pegaptanib sodium, bevacizumab, ranibizumab, aflibercept within 120 days prior to baseline
History of vitreous surgery in the study eye
History of cataract surgery within 3 months of enrollment.
History of YAG capsulotomy within 2 months of enrollment.
Visual acuity \<20/400 in the fellow eye
Uncontrolled glaucoma (pressure \>30) despite treatment with glaucoma medications.
History of cerebral vascular accident or myocardial infarction within 3 months prior to Day 0.
Clareo Health | Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab
